<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02638142</url>
  </required_header>
  <id_info>
    <org_study_id>DIUR-AHF</org_study_id>
    <nct_id>NCT02638142</nct_id>
  </id_info>
  <brief_title>Loop Diuretic Therapy in Acutely Decompensated Heart Failure</brief_title>
  <acronym>DIUR-AHF</acronym>
  <official_title>Continuous Versus Bolus Intermittent Loop Diuretic Infusion in Acutely Decompensated Heart Failure: Evaluation of Renal Function, Congestion Signs, BNP and Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Siena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera di Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Madonna della Navicella</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Siena</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DiurHF is a prospective, multicenter, observational, study that compares continuous with
      intermittent infusion of furosemide in patients admitted with a diagnosis of ADHF. Previous
      pilot study design was planned to anticipate a larger multicenter trial able to definitively
      evaluate the optimal loop diuretic use strategy in patients with ADHF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of intravenous loop diuretics is a cornerstone of therapy for acutely decompensated
      heart failure (ADHF); significant concerns have been raised regarding risks and benefits of
      loop diuretics, particularly about dosage and administration regimen.

      Recent guidelines recommend the use of these drugs to reduce left ventricular filling
      pressure, avoid pulmonary edema, and alleviate peripheral fluid retention.

      Some studies have provided guidelines for the administration of these drugs in clinical
      practice, but data interpretation remains challenging due to the frequent exclusion of
      patients with kidney disease from major ADHF clinical trials. Therefore, it is not clear if
      continuous infusion is better than intermittent boluses in terms of decongestion, maintenance
      of renal filtration function and prognosis.

      On the other hand, continuous administration should provide a more constant delivery of the
      drug into the tubule, potentially reducing these phenomena.

      The aim of the study is to evaluate the better loop diuretic intravenous administration in
      terms of renal function, congestion signs, BNP and outcome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac death and rehospitalization for HF</measure>
    <time_frame>180 days</time_frame>
    <description>Number of participant who are affected by cardiovascular death or rehospitalization within 180 days from discharge.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>length of hospital stay (days)</measure>
    <time_frame>From date of randomization until the discharge (7-12 days)</time_frame>
    <description>evaluation of length of hospital stay (days) in the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inotropes agents</measure>
    <time_frame>From date of randomization until the discharge (7-12 days)</time_frame>
    <description>Need to use inotropes agents during the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypertonic saline solution</measure>
    <time_frame>From date of randomization until the discharge (7-12 days)</time_frame>
    <description>need to use hypertonic saline solution during the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>From date of randomization until the discharge (7-12 days)</time_frame>
    <description>changes of renal function in terms of creatinine and estimated glomerular filtration rate (eGFR) comparing continuous vs intermittent administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight changes</measure>
    <time_frame>from admission to discharge (7-12 days)</time_frame>
    <description>Body weight changes in two groups from the admission to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diuresis</measure>
    <time_frame>from admission to discharge (7-12 days)</time_frame>
    <description>mean urine output in two groups from the admission to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BNP changes</measure>
    <time_frame>From date of randomization until the discharge (7-12 days)</time_frame>
    <description>mean paired changes of B-type natriuretic peptide (BNP) in the two groups during hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BUN changes</measure>
    <time_frame>From date of randomization until the discharge (7-12 days)</time_frame>
    <description>mean paired changes of blood urea nitrogen (BUN) in the two groups during hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of edema</measure>
    <time_frame>From date of randomization until the discharge (7-12 days)</time_frame>
    <description>Evaluation of edema regression (or not) after treatment in the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of dyspnea</measure>
    <time_frame>From date of randomization until the discharge (7-12 days)</time_frame>
    <description>Evaluation of dyspnea scale reduction (or not) after treatment in the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regression of pulmonary congestion</measure>
    <time_frame>From date of randomization</time_frame>
    <description>Evaluation of pulmonary congestion regression (or not) after treatment in the two groups, considering Chest X-ray at admission and at discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diuretic efficiency: (Weight loss/days of infusion)/ (Mean daily furosemide dosage/40 mg of furosemide)</measure>
    <time_frame>From hospital admission until the discharge (7-12 days)</time_frame>
    <description>Evaluation of persistence of congestion (or not) and incidence of AKI (or not) according to quartiles of diuretic efficiency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High (&gt; 125 mg/die) versus low (&lt;125 mg/die) intravenous diuretic dosage</measure>
    <time_frame>180 days</time_frame>
    <description>Number of patients with high in-hospital diuretic dosage who were affected by adverse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diuretic efficiency: (Weight loss/days of infusion)/ (Mean daily furosemide dosage/40 mg of furosemide)</measure>
    <time_frame>180 days</time_frame>
    <description>Number of patients (according quartiles of diuretic efficiency) who were affected by adverse outcome.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Continuous Furosemide Infusion</arm_group_label>
    <description>continuous intravenous furosemide infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermittent Furosemide Infusion</arm_group_label>
    <description>bolus intermittent intravenous furosemide infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Continuous Furosemide Infusion</intervention_name>
    <description>Intravenous continuous Furosemide infusion</description>
    <arm_group_label>Continuous Furosemide Infusion</arm_group_label>
    <other_name>cIV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intermittent Furosemide Infusion</intervention_name>
    <description>Intravenous bolus intermittent Furosemide Infusion</description>
    <arm_group_label>Intermittent Furosemide Infusion</arm_group_label>
    <other_name>iIV</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients who met diagnostic criteria for ADHF, independently from systolic function by
        exhibiting: at least one symptom at rest between dyspnea, orthopnea, peripheral edema and
        major fatigue; and at least two clinical signs including rales, pulmonary congestion on
        chest radiography, jugular vein dilatation and a third heart sound. An elevation in blood
        BNP &gt;100 pg/ml was considered supportive for a diagnosis of ADHF
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years;

          -  Patients with diagnosis of ADHF(dyspnea, orthopnea, peripheral edema or major fatigue
             and at least two clinical signs including rales, hepatomegaly, pulmonary congestion on
             chest radiography, jugular vein dilatation, or a third heart sound);

          -  Blood BNP &gt; 100 pg/mL;

        ADHF: Acute Decompensated Heart Failure; BNP: B-type Natriuretic Peptide; IV: IntraVenous;
        LVEF: Left Ventricular Ejection Fraction.

        Exclusion Criteria:

          -  Patients who receive more than 40 mg of IV furosemide;

          -  End-Stage renal disease or renal replacement therapy;

          -  Recent myocardial infarction (within thirty days of screening);

          -  Systolic blood pressure &lt; 80 mmHg;

          -  Creatinine levels &gt; 4 mg/dL;

          -  Patients affected by sepsis, liver diseases, inflammatory diseases or neoplastic
             diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Palazzuoli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Siena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alberto Palazzuoli, MD</last_name>
    <phone>+390577585363</phone>
    <email>palazzuoli2@unisi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gaetano Ruocco, MD</last_name>
    <phone>+393386577898</phone>
    <email>gmruocco@virgilio.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale Madonna della Navicella</name>
      <address>
        <city>Chioggia</city>
        <state>Venezia</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Valle, MD</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Valle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgio Vescovo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Giorgio Vescovo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rome La Sapienza</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Di Somma, MD</last_name>
      <phone>+3906.33775581</phone>
      <email>salvatore.disomma@uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Salvatore Di Somma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine, Cardiovascular Diseases Unit</name>
      <address>
        <city>Siena,</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Palazzuoli, MD</last_name>
      <phone>+39577585363</phone>
      <email>palazzuoli2@unisi.it</email>
    </contact>
    <investigator>
      <last_name>Alberto Palazzuoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gaetano Ruocco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Palazzuoli A, Pellegrini M, Ruocco G, Martini G, Franci B, Campagna MS, Gilleman M, Nuti R, McCullough PA, Ronco C. Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial. Crit Care. 2014 Jun 28;18(3):R134. doi: 10.1186/cc13952.</citation>
    <PMID>24974232</PMID>
  </results_reference>
  <results_reference>
    <citation>Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O'Connor CM; NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 Mar 3;364(9):797-805. doi: 10.1056/NEJMoa1005419.</citation>
    <PMID>21366472</PMID>
  </results_reference>
  <results_reference>
    <citation>Lala A, McNulty SE, Mentz RJ, Dunlay SM, Vader JM, AbouEzzeddine OF, DeVore AD, Khazanie P, Redfield MM, Goldsmith SR, Bart BA, Anstrom KJ, Felker GM, Hernandez AF, Stevenson LW. Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). Circ Heart Fail. 2015 Jul;8(4):741-8. doi: 10.1161/CIRCHEARTFAILURE.114.001957. Epub 2015 Jun 3.</citation>
    <PMID>26041600</PMID>
  </results_reference>
  <results_reference>
    <citation>ter Maaten JM, Dunning AM, Valente MA, Damman K, Ezekowitz JA, Califf RM, Starling RC, van der Meer P, O'Connor CM, Schulte PJ, Testani JM, Hernandez AF, Tang WH, Voors AA. Diuretic response in acute heart failure-an analysis from ASCEND-HF. Am Heart J. 2015 Aug;170(2):313-21. doi: 10.1016/j.ahj.2015.05.003. Epub 2015 May 9.</citation>
    <PMID>26299229</PMID>
  </results_reference>
  <results_reference>
    <citation>Voors AA, Davison BA, Teerlink JR, Felker GM, Cotter G, Filippatos G, Greenberg BH, Pang PS, Levin B, Hua TA, Severin T, Ponikowski P, Metra M; RELAX-AHF Investigators. Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF. Eur J Heart Fail. 2014 Nov;16(11):1230-40. doi: 10.1002/ejhf.170. Epub 2014 Oct 7.</citation>
    <PMID>25287144</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2015</study_first_submitted>
  <study_first_submitted_qc>December 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <last_update_submitted>June 3, 2017</last_update_submitted>
  <last_update_submitted_qc>June 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Siena</investigator_affiliation>
    <investigator_full_name>Alberto Palazzuoli MD PhD</investigator_full_name>
    <investigator_title>Medical Doctor, Cardiologist</investigator_title>
  </responsible_party>
  <keyword>loop diuretic</keyword>
  <keyword>heart failure</keyword>
  <keyword>renal dysfunction</keyword>
  <keyword>congestion signs</keyword>
  <keyword>BNP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

